T obacco smoking causes high rates of mortality and morbidity throughout the world. Despite the availability of smokingcessation medications, maintenance of long-term abstinence is difficult, and most individuals who attempt to quit smoking relapse. Although tobacco smoke contains many substances, researchers and policymakers agree that nicotine is a major cause of tobacco dependence. Understanding the neural substrates of nicotine dependence is essential for the development of more effective antismoking medications than those currently available. This article focuses on the neural substrates, especially nicotinic acetylcholine receptors, that mediate the reinforcing effects of nicotine and the development of nicotine dependence.
and conditioned effects, may also contribute to the habit-nicotine certainly plays a major role in tobacco dependence (Stolerman and Jarvis, 1995; Rose, 2006) . This review discusses: (1) the interaction of nicotine with neuronal pathways in the brain that leads to the initiation and maintenance of the tobacco-smoking habit, (2) the adaptations in several neurotransmitter systems that result from chronic nicotine exposure and lead to continued smoking and the development of nicotine dependence, and (3) the implications of these interactions and neuroadaptations for the design and discovery of novel smoking-cessation treatments.
THREE PHASES OF NICOTINE DEPENDENCE Nicotine dependence is characterized by three phases: • Acquisition and maintenance of nicotine-taking behavior:
In humans, the administration of nicotine through tobacco smoking produces a mild pleasurable rush, mild euphoria, increased arousal, decreased fatigue, and relaxation (Henningfield et al., 1985) . These reinforcing effects play an important role in the initiation and maintenance of tobacco smoking (Watkins et al., 2000; Markou, 2008) . Several other species, such as rats and nonhuman primates, exhibit behavioral evidence of nicotine reinforcement by reliably self-administering intravenous nicotine (Rose and Corrigall, 1997) . • 
Withdrawal symptoms upon cessation of nicotine intake:
Chronic nicotine use induces neuroadaptations in the brain's reward system that result in the development of nicotine dependence. Thus, nicotine-dependent smokers must continue nicotine intake to avoid distressing somatic and affective withdrawal symptoms. Newly abstinent smokers experience symptoms such as depressed mood, anxiety, irritability, difficulty concentrating, craving, bradycardia, insomnia, gastrointestinal discomfort, and weight gain (Shiffman and Jarvik, 1976; Hughes et al., 1991) . Experimental animals, such as rats and mice, exhibit a nicotine withdrawal syndrome that, like the human syndrome, includes both somatic signs and a negative affective state (Watkins et al., 2000; Malin et al., 2006) . The somatic signs of nicotine withdrawal include rearing, jumping, shakes, abdominal constrictions, chewing, scratching, and facial tremors. The negative affective state of nicotine withdrawal is characterized by decreased responsiveness to previously rewarding stimuli, a state called anhedonia.
• Vulnerability to relapse: Abstinent smokers remain prone to relapse for weeks, months, or even years after cessation of tobacco smoking. Resumption of smoking, like relapse to other drugs of abuse, often occurs upon exposure to people, places, objects, or other stimuli that individuals have learned to associate with the positive rewarding effects of the drug (Hughes et al., 2004) . Stress and cigarette smoking itself can also precipitate resumption of habitual smoking.
Comprehensive medication therapy for nicotine dependence will have to target all three phases of drug dependence. Whether by a single "magic bullet" or a sequential strategy using multiple medications, such therapy will need to attenuate the reinforcing effects of nicotine, alleviate the negative affective and somatic symptoms of withdrawal, strengthen abstinence behaviors, and block relapse to smoking. To do so, the medication or medications will need to act upon the neurobiological substrates that underlie each of those aspects of nicotine dependence. The remainder of this review focuses on our current knowledge of these substrates and their potential as targets for smoking-cessation medications.
THE ROLE OF NICOTINIC RECEPTORS
Nicotine influences mood, cognition, and body function by binding to and activating nicotinic acetylcholine receptors (nAChRs) located on neurons in the brain (Figures 1 and 2) . When activated by either nicotine or the endogenous neurotransmitter acetylcholine, the nAChR opens a channel that allows ions to pass through the neuron's membrane from the exterior to the interior of the cell and trigger changes that activate the cell. In this section, we examine the interactions of nicotine with nAChRs and the possibility of treating nicotine dependence by altering these interactions.
Nicotine produces rewarding effects by interacting with nAChRs on neurons in the brain's mesolimbic reward system. This system comprises dopaminergic neurons that originate in the ventral tegmental area (VTA) and release the neurotransmitter dopamine in regions involved in information processing, memory, and emotions, such as the nucleus accumbens (NAc), hippocampus, amygdala, and prefrontal cortex (PFC). Increases in dopamine levels within the mesolimbic system give rise to rewarding effects. Nicotine directly enhances dopamine levels in the mesolimbic system by interacting with nAChRs on the dopaminergic neurons and causing γthem to release more of the neurotransmitter (Balfour, 2009; Barrett et al., 2004; Koob and Volkow, 2010) . Nicotine also modulates dopamine release indirectly by binding to nAChRs located on excitatory glutamatergic and inhibitory gamma aminobutyric acid (GABAergic) neurons in the VTA. These glutamatergic and GABAergic neurons originate from a number of brain areas, such as the NAc, hippocampus, PFC, amygdala, ventral pallidum, and pedunculopontine tegmental nucleus, and regulate the activity of dopaminergic neurons.
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In contrast, binding of nicotine to nAChRs located on excitatory glutamatergic terminals results in glutamate release, which in turn stimulates dopaminergic neurons. Binding of nicotine to nAChRs located on inhibitory GABAergic projections leads to the release of gamma aminobutyric acid (GABA), which in turn inhibits dopaminergic neurons. Both glutamate and GABA neurotransmission play important roles in the development of nicotine dependence (for a review, see Markou, 2008) . nAChRs are also present on neurons that release other neurotransmitters, including opioids, norepinephrine, serotonin, orexin, and cannabinoids, but the role of these neurotransmitter systems in nicotine dependence has not been extensively studied.
Nicotinic Receptor Subunits and Nicotine Reinforcement
The ability of nicotine to activate a particular nAChR depends on the subunits that make up the receptor. nAChR subunits exist in 12 isoforms (variant forms), labeled α2-α10 and γβ2-β4 (Figure 1 ; Dani and Bertrand, 2007) . Every nAChR consists of five subunit molecules arranged in a ring around a central channel that opens to admit ions when the receptor is activated. In some nAChRs, called homomeric nAChRs, all five subunits are the same-for example, all are α7. Other nAChRs, called heteromeric, have a mix-for example, two α4 and three β2 subunits. The mix of subunits in each nAChR gives the receptor its distinct pharmacological properties, including its response to nicotine stimulation.
Extensive preclinical evidence suggests that β2-, α4-, α5-, α6-, and α7-containing nAChRs mediate the reinforcing and behavioral effects of nicotine (Fowler et al., 2008; Markou, 2008) . Here we briefly summarize this evidence (Figure 2 ):
• β2-containing nAChRs: Mice that lack the β2 nAChR subunit as a result of genetic manipulation, called β2 knockout mice, do not self-administer nicotine (Picciotto et al., 1998) . However, β2 knockout mice begin to self-administer nicotine when the missing receptor subunit is introduced into their brains with another genetic manipulation. Furthermore, rats treated with a compound that blocks the action of nicotine at α4β2-containing nAChRs self-administer less nicotine than control animals given an inert vehicle like saline.
• α5-containing nAChRs: Mice bred to lack the α5 subunit (i.e., α5 knockout mice) had fewer nicotineinduced seizures and attenuated nicotine-induced locomotor activity compared with wildtype mice. Importantly, α5 knockout mice showed increased nicotine self-administration compared with wildtype mice. This work by Fowler and colleagues (2011) suggests that activity of the α5 subunit in the medial habenula-interpeduncular nucleus pathway reduces the aversive effects of high doses of nicotine. Humans who have a single-nucleotide polymorphism (SNP) in the gene for the α5 subunit that decreases the expression of the α5-containing nAChRs are twice as likely as those without this SNP to develop nicotine dependence. Taken together with the animal findings, this pattern of results suggests that agonists of α5-containing nAChRs or other compounds that increase the activity of α5-containing nAChRs may promote smoking ces- sation by enhancing the aversive effects of nicotine.
• α6-containing nAChRs: Compounds that selectively reduce the activity of α6-containing nAChRs dosedependently decrease nicotine self-administration in rats, suggesting these nAChRs are important in nicotine's reinforcing effects (Dwoskin et al., 2009 ).
• α7-containing nAChRs: Rats self-administered less nicotine after systemic administration of a compound that prevents nicotine from interacting with predominantly homomeric α7-containing nAChRs (Markou and Paterson, 2001) . These results suggest a role for α7-containing nAChRs in the reinforcing effects of nicotine. In summary, activation of nAChRs that contain β2, α4, α6, or α7 subunits appears to promote the reinforcing effects of nicotine. By contrast, α5-containing nAChRs appear to limit nicotine reinforcement, possibly by mediating the drug's aversive effects. An important unanswered question is whether every nAChR that contains one of these subunits contributes to nicotine reinforcement, or whether only subsets of these nAChRs are involved. Ultimately, the complete subunit composition and stoichiometry of nAChRs containing these five subunits needs to be fully understood to develop medications that will block the reinforcing effects of nicotine and promote smoking cessation.
Nicotinic Receptor Subunits and Nicotine Withdrawal
Evidence from rodent models and genetically modified mice suggests that nAChRs and their various subunits mediate the aversive somatic and negative affective 
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A.
B. signs of nicotine withdrawal (for reviews, see Kenny and Markou, 2001; Fowler et al., 2008) . For example, nicotine-dependent rats treated with a compound that blocks α4β2-containing nAChRs exhibited a negative affective or depression-like state, during which they were less responsive to electrical stimulation of their reward system but showed no somatic signs of nicotine withdrawal (Epping-Jordan et al., 1998) . By contrast, nicotine-dependent rats treated with a compound that blocks multiple nAChR subtypes, including β4-containing nAChRs, exhibited both a depression-like state and somatic signs of nicotine withdrawal. Importantly, experiments with knockout mice suggest that nAChRs containing α5, α7, and β4 subunits are instrumental in the expression of somatic signs of nicotine withdrawal, whereas β2-containing nAChRs contribute to the nicotine withdrawal-induced negative affective state (Fowler et al., 2008) .
Nicotinic Receptor-Based Treatment Strategies
Developers of antismoking medications have long focused on compounds that interact with nAChRs (see Table 1 ). Varenicline, for example, is a partial agonist at α4β2-containing nAChRs. Varenicline attenuates the reinforcing effects of nicotine by occupying the binding sites on these receptors and blocking nicotine from binding to them. Varenicline and other partial agonists also weakly stimulate α4β2-containing nAChRs, thereby reducing withdrawal symptoms.
On the basis of the preclinical literature discussed above, compounds that act at nAChRs that contain the β2, α5, α7, and β4 subunits have the potential to reduce the negative affective and aversive somatic symptoms of nicotine withdrawal.
Researchers are also exploring the potential for a new generation of smoking-cessation therapies based on allosteric modulation of nAChRs (Yoshimura et al., 2007) sites on nAChRs. Allosteric compounds acting at these sites may either help to reduce the reinforcing effects of nicotine or may alleviate the aversive effects of nicotine withdrawal, or both, and thus may help prevent relapse (Taly et al., 2009 ).
Other promising strategies currently under investigation aim to inhibit stimulation of nAChRs by reducing the amount of nicotine that reaches the brain. These include immune-based approaches, such as nicotine vaccines and pharmacokinetic treatments that alter the availability of nicotine by enhancing its peripheral metabolism and clearance (Xi et al., 2009 ).
NEUROTRANSMITTER SYSTEMS IN NICOTINE ADDICTION
As described above, nicotine initiates the processes leading to nicotine dependence by interacting with nAChRs on dopaminergic, glutamatergic, and GABAergic neurons. Accordingly, as discussed, one set of potential medication strategies for treating nicotine dependence focuses on modulating the nicotine-nAChR interaction. A second group of potential strategies targets the receptors and transporters that mediate the effects of dopamine, glutamate, and GABA after exposure to nicotine.
Dopamine
Dopamine has been strongly implicated in the reinforcing and withdrawal effects of nicotine. The key evidence includes experiments in laboratory animals that show:
• administering nicotine increases dopamine transmission within the mesolimbic reward system; and • administering compounds that block dopamine binding to its receptors (D1, D2, D3, D4, and D5 receptors) decreases the reinforcing effects of nicotine. Dopaminergic neurotransmission is decreased during nicotine withdrawal. For example, in nicotine-dependent rats, the induction of nicotine withdrawal by administration of the nAChR antagonist mecamylamine resulted in decreased dopamine levels in the NAc compared with administration of an insert substance (Hildebrand et al., 1998) . In addition, the decrease in NAc dopamine correlated well with the somatic and affective signs of nicotine withdrawal. The decrease in NAc dopamine was greater in adult rats compared with adolescent rats (Natividad et al., 2010) , possibly indicating a more important role for mesolimbic dopamine in nicotine withdrawal in adult rats compared with adolescent rats. Dopamine-based smoking-cessation medications that are currently available or under development are directed toward either alleviating nicotine withdrawal symptoms, blocking nicotine reinforcement, or both (see box,Treatment Strategies for Nicotine Dependence Based on Dopaminergic Neurotransmission).
Glutamate
Glutamate, the brain's primary excitatory neurotransmitter, also plays a critical role in the development of nicotine dependence (Liechti and Markou, 2008) . Nicotine increases the release of glutamate by binding to excitatory α7-containing nAChRs located on presynaptic terminals of glutamatergic neurons in the VTA, NAc, amygdala, hippocampus, and PFC .The released glutamate binds to ionotropic and metabotropic glutamate receptors located on neurons in these areas (Figure 2 ).
Glutamate and nicotine reinforcement
Glutamate released into the VTA after nicotine administration binds to glutamate receptors on dopaminergic neurons. The resulting increased firing of VTA dopaminergic neurons leads to dopamine release in the NAc and, consequently, nicotine reward (Grillner and Svensson, 2000) . The rewarding effect of nicotine can be attenuated by administering compounds that reduce glutamate
TREATMENT STRATEGIES FOR NICOTINE DEPENDENCE BASED ON DOPAMINERGIC NEUROTRANSMISSION Alleviation of withdrawal symptoms by blockade of dopamine uptake transporter
Bupropion is approved by the Food and Drug Administration (FDA) as a smoking cessation medication. It acts by blocking the uptake of synaptic dopamine via the dopamine transporter (DAT). In addition to blocking dopamine uptake, bupropion has other potentially therapeutic actions, such as blockade of nicotinic acetylcholine receptors and norepinephrine uptake (Paterson, 2009) . Clinically, bupropion alleviates negative affective symptoms associated with smoking cessation, such as depression, difficulty in concentrating, and irritability.
Attenuation of the reinforcing effects of nicotine via blockade of dopamine receptors
Blocking the reinforcing effects of nicotine using a dopamine receptor antagonist is another dopamine-based strategy that can be developed for smoking cessation (Figure 2, page 7) . Blockade of D1, D2, and D3 dopaminergic receptors decreases nicotine self-administration. There is considerable interest in D3 receptor antagonists because this subtype of dopamine receptors has high affinity for dopamine and is extensively expressed in the mesolimbic dopamine system (Diaz et al., 2000) . Another reason for the interest in D3 dopamine receptors is that D1 and D2 receptor antagonists tend to produce adverse effects in humans. (Liechti and Markou, 2008 ).
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• activate presynaptic inhibitory mGlu2/3 receptors.
Furthermore, rats treated with glutamate receptor antagonists showed reduced nicotine-induced dopamine release compared with rats receiving an inert substance (Fu et al., 2000) . These findings suggest that decreasing glutamate transmission can facilitate smoking cessation by decreasing the reinforcing effects of nicotine.
Glutamate and nicotine withdrawal
Withdrawal after chronic nicotine exposure is characterized by decreased glutamate transmission and compensatory changes in glutamate receptors . For example, rats exhibited decreased expression of NMDA ionotropic glutamate receptor subunits, as well as decreased functioning of mGlu2/3 receptors in the PFC, during early withdrawal following chronic nicotine self-administration (Kenny et al., 2009; Liechti et al., 2007) . Because presynaptic mGlu2/3 receptors reduce glutamate release when activated, the decreased functioning of mGlu2/3 receptors appears to be a compensatory mechanism to offset the reduction in synaptic glutamate levels that occurs during early withdrawal.
Similarly, rats in early withdrawal after chronic nicotine self-administration exhibited downregulation of the glutamate transporter (GLT1) in the NAc and cystine-glutamate transporter (xCT) in the VTA and NAc (Knackstedt et al., 2009 ). These transport proteins are located on glial cells and have opposite roles in the regulation of synaptic glutamate levels. GLT1 decreases synaptic glutamate by drawing glutamate out of the synapse into the glia; by contrast, xCT extrudes vesicular glutamate from glia in exchange for synaptic cystine. The downregulation of GLT1 and xCT during nicotine withdrawal are therefore examples of compensatory mechanisms in response to synaptic glutamate depletion that occurs after chronic nicotine exposure.
In summary, preclinical data suggest that withdrawal from chronic nicotine exposure is characterized by decreased glutamatergic transmission. Thus, medications that increase synaptic glutamate levels may help to alleviate withdrawal symptoms in abstinent smokers.
Glutamate and cue-induced relapse As described above, memory associations that link certain people, places, and things with the rewarding effects of smoking can trigger intense cravings that lead to relapse in abstinent smokers. In animals, exposure to cues previously associated with nicotine can enhance mesolimbic glutamatergic neurotransmission, resulting in the resumption of drug-seeking behavior (Kalivas and O'Brien, 2008) . Treating animals with compounds that block glutamatergic neurotransmission suppresses this effect (Liechti and Markou, 2008) . Accordingly, one strategy to prevent relapse in humans is to administer compounds that block glutamatergic neurotransmission.
Unfortunately, learned associations that induce craving cannot be easily erased. Therefore one approach to help smokers maintain abstinence is to replace memories that link stimuli to smoking and the reward effects of nicotine with new memories that will not induce craving or raise the risk of relapse (Taylor et al., 2009 ). This type of learning, which decreases the reward value of stimuli previously associated with smoking, is called extinction learning (Myers et al., 2011) . Interestingly, increasing glutamate transmission facilitates extinction learning. Therefore, another strategy to prevent relapse in abstinent smokers is to aid extinction learning via administration of compounds that increase glutamatergic neurotransmission. Table 2 lists specific glutamate-based strategies that target the different glutamatergic receptors and transporters for the treatment of nicotine dependence (see also Figure  2 ). Major preclinical findings that involve glutamatergic substrates are described below (for a more detailed review, see Liechti and Markou, 2008) : mGlu2/3 receptors Administration of an mGlu2/3 receptor agonist in rats decreases nicotine self-administration. Furthermore, such administration decreased reinstatement of nicotine-seeking behavior upon exposure to cues previously associated with the effects of nicotine (Liechti et al., 2007) . These findings suggest that mGluR2/3 receptor agonists may help promote smoking cessation and prevent relapse in humans.
Glutamate-based treatment strategies
However, the attenuating effects of mGlu2/3 receptor agonists on nicotine self-administration in rats waned after repeated administration. This loss of effectiveness suggests the development of tolerance that may limit the therapeutic utility of full agonists at mGlu2/3 receptors. Currently, positive allosteric modulators for mGlu2/3 receptors are available and are being evaluated clinically for other indications, including treatment of schizophrenia. mGlu2/3 receptor positive allosteric modulators may prove to be more suitable than the full mGlu2/3 receptor agonists. However, the utility of these compounds as potential antismoking medications still needs to be determined both preclinically and clinically.
As described above, animals exhibit a depression-like state upon withdrawal from chronic nicotine exposure. That state is attributed to a decrease in glutamatergic neurotransmission. In animal studies, administration of compounds that increase glutamatergic neurotransmission by blocking presynaptically located inhibitory mGlu2/3 receptors reversed the depression-like state associated with nicotine withdrawal. Thus, mGluR2/3 antagonists may be useful for treating the negative affec-tive symptoms resulting from smoking abstinence in humans.
mGlu5 receptors
Administration of compounds that block the mGlu5 receptors decrease the self-administration of nicotine and attenuate the reward-enhancing effects of nicotine in rats Paterson et al., 2003) , suggesting that mGlu5 receptor antagonists decrease the reinforcing effects of nicotine. Administration of mGlu5 receptor antagonists in rats also blocked the reinstatement of nicotine-seeking behavior in response to cues previously associated with nicotine, suggesting that these compounds may help prevent relapse in humans (Markou, 2008) .
However, administration of mGlu5 receptor antagonists aggravated the depression-like state and somatic signs associated with nicotine withdrawal in rats. Furthermore, at the highest tested dose, mGlu5 receptor antagonists on their own induced a depression-like state in nicotine-naïve rats. Thus, these compounds may have negative affective effects in humans. Taken together, these data suggest that, in humans, mGlu5 receptor antagonists may promote smoking cessation and prevent relapse after a period of abstinence but may worsen the symptoms of early nicotine withdrawal.
Negative allosteric modulators of the mGlu5 receptor may prove to be better smoking-cessation aids than full antagonists. Compounds of this type are currently being clinically evaluated for indications including gastroesophageal reflux disease, migraine, and pain. Evaluation for potential use as a treatment for nicotine dependence is highly warranted.
NMDA receptors
In animals, administration of compounds that reduce glutamate neurotransmission by blocking the NMDA receptors decreased nicotine self-administration, suggesting that NMDA receptor antagonists can decrease the reinforcing effects of nicotine (Kenny et al., 2009 ). In a small study, memantine, a low-affinity NMDA receptor antagonist that also blocks some nAChRs, did not reduce cigarette smoking or craving in smokers. Unfortunately, high-affinity NMDA receptor antagonists are known to produce severe adverse neurotoxic and psychogenic effects in humans and therefore are unlikely to be developed into medications for human use.
The structure of the NMDA receptor is quite complex, and its activation requires the binding of both glutamate and a co-agonist, such as glycine. Therefore glutamate neurotransmission can also be decreased with compounds that block the binding of glycine to the NMDA receptor. In mice, administration of such a compound blocked both the acquisition and expression of preference for a nicotine-associated environment in a conditioned place preference (CPP) study. This finding suggests that compounds that occupy the glycine binding site on the NMDA receptor have the potential to decrease the reinforcing effects of nicotine and thus may help people quit smoking.
Interestingly, activation of the NMDA receptor facilitates extinction learning. There is strong preclinical evidence to suggest that administration of D-cycloserine, an NMDA receptor co-agonist that subtly activates the NMDA receptor, facilitates extinction of learned fear responses in animals (Woods and Bouton, 2006) . D-cycloserine is currently being evaluated as a treatment for people who suffer from extreme anxiety or fear (phobias) of certain places and situations in their environment (Hofmann et al., 2006) . It is hypothesized that D-cycloserine will help these people establish new learned associations that will eventually alleviate their phobias. In rats, administration of D-cycloserine facilitates extinction of cocaine seeking and cocaineinduced CPP behavior (Myers et al., 2011) . Importantly, in a small preliminary study, smokers who were given D-cycloserine had fewer cravings when exposed to smoking-related cues than smokers given a placebo (Santa Ana et al., 2009 ). However, these data are very preliminary and further investigations are required to examine whether D-cycloserine facilitates extinction of nicotine-seeking behavior.
AMPA receptors
As described previously, cessation of smoking in humans can result in negative affective symptoms, including irritability, changes in mood, and depression. These effects cause many abstinent smokers to restart the smoking habit. In nicotine-dependent rats, inhibition of glutamatergic transmission by a compound that blocks AMPA receptors decreased responsiveness to previously rewarding stimuli, resulting in the development of a depression-like state resembling nicotine withdrawal (Kenny, Gasparini, and Markou, 2003) . This finding suggests that antagonists at the AMPA receptor will worsen the negative affective symptoms that result from smoking cessation in humans. Thus, conversely, medications that stimulate AMPA receptors, such as AMPA receptor agonists or AMPA receptor positive modulators, may alleviate these negative symptoms. Interestingly, AMPA receptor positive modulators have produced antidepressant-like effects in animal models of depression (Paul and Skolnick, 2003) . Such compounds need to be evaluated clinically before conclusions can be reached about their potential utility as treatments for nicotine dependence.
Glutamate transporters
On the basis of preclinical evidence, it is hypothesized that the hypoglutamatergic state resulting from the cessation of tobacco smoking promotes nicotine-seeking behavior (Markou, 2007) . Therefore, restoring normal glutamatergic neurotransmission through manipulation of glutamate transporters, such as xCT and GLT1, may help smokers maintain abstinence. Consistent with these hypotheses, smokers in a small pilot study smoked fewer cigarettes when given a compound such as N-acetylcysteine compared with smokers who received a placebo; alcohol consumption was taken into consideration. N-acetylcysteine binds to xCT and releases glutamate into the synapse from intracellular stores in exchange for synaptic cystine (Knackstedt et al., 2009 ). However, further clinical work is required to determine if this strategy will be effective in promoting smoking cessation and preventing relapse in all smokers.
In summary, the function of the neurotransmitter glutamate has considerable promise as a target for smoking-cessation medications. In addition, compared with ionotropic glutamate receptors, metabotropic glutamate receptors are potentially excellent targets for medication development because they are slow-acting, populate brain areas involved in reward and emotion, subtly modulate glutamate transmission, and are less likely to produce undesirable side effects seen with manipulation of fast-acting ionotropic receptors (Markou, 2007) . Furthermore, allosteric modulators that subtly modulate the endogenous glutamatergic system, and thus produce fewer undesirable effects compared with full glutamate receptor agonists and antagonists, appear to have a good chance of proving useful in humans (Rudd and McCauley, 2005) . Although currently there are no FDA-approved glutamate-based smoking-cessation agents, several of these compounds are being evaluated clinically for treatment of psychiatric disorders that are associated with high rates of smoking, such as depression and schizophrenia (Conn and Jones, 2009 ). These studies may shed light on whether these compounds may also have effects on cigarette smoking.
Gamma-Aminobutyric Acid
GABA is the major inhibitory neurotransmitter in the mammalian nervous system. An increase in GABA levels in the VTA limits reward and reinforcement by reducing the activity of mesolimbic dopaminergic neurons. GABA is released in the VTA by neurons that originate in several brain areas, such as the pedunculopontine tegmental nucleus, ventral pallidum, and NAc, as well as interneurons located within the VTA itself (Kalivas and O'Brien, 2008) . Endogenous GABA acts via ionotropic GABA A and GABA C receptors and metabotropic GABA B receptors.
Role of GABA in nicotine reinforcement, withdrawal, and relapse In nicotine-naïve animals, acute nicotine exposure increases GABA release by activating excitatory γ4γ2-containing nAChRs that are located on GABAergic neurons in the VTA. Thus initially, nicotine-induced GABA release limits the rewarding effects of nicotine. By contrast, chronic nicotine exposure desensitizes γ4γ2-containing nAChRs on GABAergic receptors . Hypothetically, this desensitization will decrease nicotine-induced GABA release, leading to decreased inhibition of VTA dopaminergic neurons and increased dopamine release in the NAc -and so facilitate the reinforcing effects of nicotine. Administration of compounds that increase GABAergic neurotransmission decreases both the reinforcing effects of nicotine and reinstatement of cue-induced nicotineseeking behavior in rats (Markou, 2008; Vlachou et al., 2011) . Thus, treatments that enhance GABA transmission may prevent relapse to tobacco smoking.
GABA-based treatment strategies
GABA-based drug discovery for smoking cessation has focused on increasing GABAergic transmission, either by inhibiting the breakdown of GABA or by activating GABAergic receptors (Markou, 2008;  Figure 2 ).
Inhibition of GABA breakdown
The levels of GABA can be increased irreversibly by inhibiting GABA transaminase, the primary enzyme involved in GABA metabolism. In animal studies, administration of gamma-vinyl GABA (GVG; also referred to as vigabatrin), a compound that inhibits GABA transaminase, decreased nicotine self-administration and blocked both the acquisition and expression of nicotine-induced CPP (Dewey et al., 1999) . These findings suggest that GVG reduces the reinforcing effects of nicotine. In addition, GVG dose-dependently lowered nicotine-induced increases in NAc dopamine in both nicotine-naïve and nicotine-treated rats. On the basis of these findings, it appears that GVG may help smokers quit. GVG is approved by the FDA for the treatment of infantile spasms and is currently used to treat epilepsy in many countries. However, its use is associated with serious adverse events, such as visual field defects, that may limit its utility as a smoking-cessation aid.
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GABA B receptor activation
Administration of compounds that activate GABA B receptors, such as GABA B receptor agonists, decreased nicotine self-administration in rats. Importantly, the reduction in nicotine self-administration persisted even after repeated administration of the GABA B agonist, indicating that little tolerance to its effectiveness had developed (Paterson et al., 2005) . In the same study, GABA B receptor agonists also blocked the reinstatement of nicotine-seeking behavior in rats upon re-exposure to nicotine-associated cues. Together these results suggest that GABA B receptor agonists may promote smoking cessation. Consistent with the above preclinical evidence, in a small double-blind clinical study, the GABA B receptor agonist baclofen reduced the number of cigarettes smoked per day as well as craving associated with abstinence (Franklin et al., 2009 ). However, GABA B receptor agonist administration in animals also resulted in nonspecific effects, such as decreased responding for nondrug rewards, including food and pleasurable electrical brain stimulation, and undesirable effects such as severe motor impairment. These preclinical findings suggest that GABA B receptor agonists may have limited utility for use in humans.
GABA B receptor positive allosteric modulators
Researchers are investigating the effects of modulators that bind to allosteric sites on the GABA B receptor and enhance the receptor's responsiveness to GABA. Importantly, these positive allosteric modulators tend to have more subtle effects than full agonists, which bind to the same GABA B site as GABA (Guery et al., 2007) . For example, positive allosteric modulators of GABA B receptors do not cause the severe motor impairment seen with GABA B receptor agonists.
Administration of positive allosteric modulators of GABA B receptors in rats decreased nicotine selfadministration at doses that did not affect responding for nondrug rewards such as food (Paterson et al., 2008) . Furthermore, positive allosteric modulators of GABA B receptors also blocked the cue-induced reinstatement of nicotine-seeking behavior in rats (Vlachou et al., 2011) . These findings strongly suggest that GABA B receptor positive allosteric modulators may help promote smoking cessation and prevent relapse in humans. In addition, these allosteric modulators may have better side-effect profiles than full GABA B receptor agonists.
CONCLUSIONS
Tobacco smoking is a harmful habit that can be targeted to bring down both morbidity and future health care costs. Significant progress has been made over the last 2 decades in understanding the neural substrates involved in nicotine dependence. This article has reviewed our current understanding of nAChRs and the role of nicotinic receptor subtypes in nicotine reinforcement and dependence. Preclinical work that evaluates the role of non-nAChR substrates, such as dopamine, glutamate, and GABA, in nicotine reinforcement and dependence was also reviewed. Both nAChR-based and non-nAChRbased smoking-cessation strategies are under various stages of development. Although several of these strategies need to be clinically validated, there is much ground for hope that the next generation of smoking-cessation agents will provide better medications than those currently available.
